MUTATION ANALYSIS AND HAPLOTYPE CORRELATION FOR 139 CYSTIC-FIBROSIS PATIENTS FROM THE NEBRASKA REGIONAL CYSTIC-FIBROSIS CENTER

被引:4
作者
TRAYSTMAN, MD
SCHULTE, N
COLOMBO, JL
SAMMUT, PH
REILLY, P
PATEL, C
ACQUAZZINO, D
SIMANEK, B
ANDERSON, R
KIMBERLING, WJ
SCHAEFER, GB
SANGER, WG
机构
[1] UNIV NEBRASKA, MED CTR, DEPT PEDIAT, OMAHA, NE 68198 USA
[2] BOYSTOWN NATL RES HOSP, OMAHA, NE USA
关键词
CYSTIC FIBROSIS; MUTATION ANALYSIS; HAPLOTYPE CORRELATION; HUMAN GENETICS;
D O I
10.1002/humu.1380020103
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cystic fibrosis (CF) is the most common autosomal recessive disorder in Caucasian populations with an approximate frequency of one in 2,500 live births and a carrier frequency of one in 25. We studied 400 individuals seen at The Nebraska Regional Cystic Fibrosis Center that included 139 CF patients, 206 parents, and 55 unaffected siblings to determine the frequency of the DELTAF508, R117H, G542X, S549R/N, G551D, R553X, R560T, and W1282X mutations. In addition, we determined haplotypes on each of these individual's chromosomes using four markers that included XV-2c, KM-19, pMP6d.9, and G2. Results from this study showed that the DELTAF508 mutation was present in 70% of CF chromosomes. Of the 139 CF patients 74 (53%) were homozygous for the DELTAF508 deletion, 47 (34%) were heterozygous for the DELTAF508 deletion and an unknown mutation, and 18 (13%) carried two unknown mutations. Four additional mutations were also found in our population and included G542X (6%), G551D (5%), R553X (4%), and R560T (1%). One patient was documented to be a compound heterozygote for G542X/G551D. A polymorphism, F508C, that has previously been reported in several families was also present in our study. The most common haplotype associated with the DELTAF508 deletion in our CF patients was the E haplotype (CF Consortium B) while other mutations were associated with a variety of haplotypes.
引用
收藏
页码:7 / 15
页数:9
相关论文
共 27 条
[1]  
BEAUDET AL, 1989, AM J HUM GENET, V44, P319
[2]  
Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649
[3]   CYSTIC-FIBROSIS - MOLECULAR-BIOLOGY AND THERAPEUTIC IMPLICATIONS [J].
COLLINS, FS .
SCIENCE, 1992, 256 (5058) :774-779
[4]   A CLUSTER OF CYSTIC-FIBROSIS MUTATIONS IN THE 1ST NUCLEOTIDE-BINDING FOLD OF THE CYSTIC-FIBROSIS CONDUCTANCE REGULATOR PROTEIN [J].
CUTTING, GR ;
KASCH, LM ;
ROSENSTEIN, BJ ;
ZIELENSKI, J ;
TSUI, LC ;
ANTONARAKIS, SE ;
KAZAZIAN, HH .
NATURE, 1990, 346 (6282) :366-369
[5]   MULTIPLE MUTATIONS IN HIGHLY CONSERVED RESIDUES ARE FOUND IN MILDLY AFFECTED CYSTIC-FIBROSIS PATIENTS [J].
DEAN, M ;
WHITE, MB ;
AMOS, J ;
GERRARD, B ;
STEWART, C ;
KHAW, KT ;
LEPPERT, M .
CELL, 1990, 61 (05) :863-870
[6]  
DORK T, 1991, HUM GENET, V87, P441
[7]  
HIGHSMITH WE, 1990, CLIN CHEM, V36, P1741
[8]  
HIGUCHI R, 1989, AMPLIFICATIONS, V2, P1
[9]  
Kalin N, 1992, Hum Mutat, V1, P204, DOI 10.1002/humu.1380010305
[10]   IDENTIFICATION OF MUTATIONS IN REGIONS CORRESPONDING TO THE 2 PUTATIVE NUCLEOTIDE (ATP)-BINDING FOLDS OF THE CYSTIC-FIBROSIS GENE [J].
KEREM, BS ;
ZIELENSKI, J ;
MARKIEWICZ, D ;
BOZON, D ;
GAZIT, E ;
YAHAV, J ;
KENNEDY, D ;
RIORDAN, JR ;
COLLINS, FS ;
ROMMENS, JM ;
TSUI, LC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (21) :8447-8451